A group in the National Center for Advancing Translational Sciences at the NIH led by Dr. Menghang Xia used ATCC's Angio-Ready™ to confirm the dose-dependent, anti-angiogenic effects of compounds used in a screen of HIF-1 signaling inhibitors. 

The ideal characteristics of an in vitro whole-cell model include equivalence to in vivo physiology, genotypic and karyotypic stability, high proliferative capability, and the ability to be used at high passage. Does such a cell type exist? In this blog entry, I will discuss human telomerase (hTERT)-immortalized cells (ICs), which possess all of these qualities.

Human primary cells (HPCs) are frequently disregarded as a choice for cell cultures as they typically require more technical expertise to establish in the laboratory. While HPCs may be challenging to generate, they have much in common with cells in vivo; they retain many of the secretory, barrier, contractile, and other physiological functions of their in vivo condition. When acquired from a respected biological resource center, HPC maintenance is similar to that of any other cell line, thanks to the availability of optimized media and reagent formulations, affordable cell matrix solutions, and detailed protocols.